MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.65
-0.33
-3.31%
After Hours: 9.65 0 0.00% 16:00 03/27 EDT
OPEN
9.54
PREV CLOSE
9.98
HIGH
9.79
LOW
9.15
VOLUME
129.64K
TURNOVER
--
52 WEEK HIGH
12.27
52 WEEK LOW
4.820
MARKET CAP
291.82M
P/E (TTM)
-5.2188
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SNDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNDX stock price target is 17.83 with a high estimate of 27.00 and a low estimate of 10.00.

EPS

SNDX News

More
  • Morgan Stanley Maintains Equal-Weight on Syndax Pharmaceuticals, Raises Price Target to $10
  • Benzinga · 03/11 12:32
  • The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
  • Benzinga · 03/06 13:49
  • The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
  • Benzinga · 03/05 13:14
  • Syndax Pharmaceuticals (SNDX) Presents At Cowen Health Care Conference - Slideshow
  • Seeking Alpha - Article · 03/05 12:24

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SNDX

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, is a once-weekly, oral, small molecule, Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer. The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. It is also developing SNDX-6352, a monoclonal antibody targeting the colony stimulating factor-1 receptor.
More

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.